Presented by expert speakers, our webinars will give you advance insight into topics that will be covered at the event.
Can’t make the date? Still register to receive the webinar recording afterwards.
Targeted, Controlled and Responsive Therapeutic Delivery through the Design of Self-Assembling Peptide Hydrogels
Tuesday 14th January 2020 | 02:00 PM GMT
Presented by Aline Miller, Professor, University of Manchester
- Design rules for engineering responsive peptide hydrogels
- Targeting endometriosis with sprayable peptide hydrogels
- Delivery of therapeutics to solid tumours
- Mucoadhesive hydrogels to prolong therapeutic efficacy
Aline Miller, PhD, is a Professor of Biomolecular Engineering in the School of Chemical Engineering at the University of Manchester where she has won several awards, including The Royal Society of Chemistry MacroGroup UK Young Researchers Medal, The Institute of Physics, Polymer Physics Group Young Researchers Lecture Award and the Philip Leverhulme Prize for Engineering for her work on self-assembling peptide materials. In this area she has published over 100 refereed papers, authored 5 patents and has won > £8M from research councils, EU, charities and industry to support her research group. Aline is also Chief Executive Officer and Co-Founder of Manchester BIOGEL, a company specialising in providing engineered, self-assembling peptide hydrogels for 3D cell culture, 3D bioprinting and incorporation within medical devices. She currently oversees all aspects of the business from product production and development, to marketing and sales, to ensure our customers receive the very best product and service.
Our free webinar is for peptide professionals based in the UK, EU and US interested in learning more about the opportunities and challenges that exist within peptide targeted therapeutic delivery. This is a free event open to all, so why not register and benefit from the expertise of our speakers.
Discovery & Clinical Collaborations In Biotherapeutics
Wed, Jan 29, 2020 4:00pm GMT
Speaker 1: Robin Löving, Chief Scientific Officer, Salipro Biotech
Speaker 2: Denise Steckel, Head, Clinical Collaborations Management, Genentech
The majority of small-molecule drugs target multispanning membrane proteins. However, it’s been difficult to generate functional monoclonal antibodies (mAbs) against this group of targets. As a result, only a few therapeutic antibodies have been approved when targeting this important class of drug targets, including GPCRs, Ion Channels and Transporters.
The key to make functional mAbs is to use pure, native, homogeneous antigen for immunization, mAb selection/sorting and for in vitro HTS characterization. The Salipro® nano-membrane technology enables all the above for fragile membrane protein targets. In addition, Salipro® represents a validated approach for membrane protein epitope mapping by cryo-EM. Working with Salipro® allows to unlock entirely novel opportunities in drug discovery and antibody development.
- Why we do combination trials
- Working with Collaborators to optimize performance
- Key factors for success in Collaborator work
- Advantages, Challengers & Lessons learned to date on the is journey
Our free Oxford Global webinar is for protein & antibody professionals based in the UK, EU and US interested in learning more about the discovery of novel therapeutics. This is a free event open to all, so why not register and benefit from joining this live event?
Bispecific Antibodies Targeting The Innate Immune Checkpoint CD47
Tue 21st January 2pm UK time
Presented by Nicolas Fischer, Chief Executive Officer, Light Chain Bioscience
Our free Oxford Global webinar is for bispecific antibody professionals based in the UK, EU and US interested in learning more about targeting innate immune checkpoints with bispecific antibodies. This is a free event open to all, so why not register and benefit from joining this live event?
After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering. At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience